▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Nash Videos
Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective
This multidisciplinary discussion on the diabetologist's and hepatologist's perspectives of non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), involves international experts, Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom and Prof. Christophe Moreno, together with the chair, Professor Manuel Castor Cabezas. The review addresses NAFLD as a multisystem disease, its epidemiology globally and the significance of developing multidisciplinary care paths.
View More ⏩Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective
Non-Invasive Evaluation of NAFLD Severity
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are a leading cause of liver diseases worldwide, including hepatocellular carcinoma (HCC). In this review on non-invasive evaluation, Prof. Jérôme Boursier, France, presents a meta analysis focusing on the identification of patients with high risk profile and in need of specific management. Dr. Boursier reviews the two major families of non-invasive tests and discusses the sequential use of tests recommended in the EASL guidelines 2021.
View More ⏩Non-Invasive Evaluation of NAFLD Severity
NIT for screening, referral & diagnosis of NAFLD
Liver fibrosis is the major driver in liver disease progression. Prof. Romero-Gómez, Spain, reviews on NoninvasiveTests - NITs for screening, referral, and diagnosis of nonalcoholic fatty liver disease.
View More ⏩NIT for screening, referral & diagnosis of NAFLD
NAFLD/NASH as a metabolic disease: improving patients outcomes
Prof. Maarten Tushuizen, Netherlands, discusses the current treatment strategies for non-alcoholic fatty liver disease (NAFLD) and explains as well as future therapeutic approaches. Non-invasive tests (NITs) for staging the continuum of NAFLD / NASH are critical as well as establishing effective care pathways.
View More ⏩NAFLD/NASH as a metabolic disease: improving patients outcomes
Clinical Data Warehouse : definitions and use cases
Prof. Stéfan Darmoni, France, discusses the clinical data warehouses (CDW) where he explains its definitions and various use cases.
View More ⏩Clinical Data Warehouse : definitions and use cases
NAFLD / NASH as a Metabolic Disease: Improving Patients Outcomes – Part 2
Prof. A.G.(Onno) Holleboom, Netherlands, discusses non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as a metabolic disease and reviews management strategies in order to improve patients outcomes.
View More ⏩NAFLD / NASH as a Metabolic Disease: Improving Patients Outcomes – Part 2
Cancers and NASH
Dr. Jean-François Dufour (Switzerland) reviews the association between cancers and NASH, where he highlights the causes of death in NAFLD patients, in which cardiovascular diseases and non-liver cancer with 38.3% and 18.7% are identified as some of the major causes.
View More ⏩Cancers and NASH
Link between NAFLD and HFpEF
Dr. Marat Fudim (USA) reviews the interaction between NAFLD and Heart Failure with preserved Ejection Fraction (HFpEF), including highlights of the global prevalence rate of NAFLD.
View More ⏩Link between NAFLD and HFpEF
Interactions between gut microbiota and PPARs in NAFLD
Dr. Nicolas Lanthier (Belgium) reviews the interaction between the gut microbiota and PPARs in NAFLD. He discusses the microbiota and its link to NAFLD and IR, where he explains the key role of the gut microbes in the metabolism of their host and highlights how liver becomes the first organ to be exposed to gut changes.
View More ⏩Interactions between gut microbiota and PPARs in NAFLD
Lifestyle Treatment for NAFLD in Daily Practice
Pr Zelber Sagi explains there is an option for life's treatment at each stage of non-alcoholic fatty liver disease NAFLD with lifestyle examples in clinical practice.
View More ⏩Lifestyle Treatment for NAFLD in Daily Practice
NASH and CV disease: new considerations
NASH is increasing with the current obesity pandemic. Prof. Robert Chilton (San Antonio - USA) reminds us that the current best practices to tackle the burden of this multi-system disease are currently lifestyle interventions
View More ⏩NASH and CV disease: new considerations
New insights into the role of inflammation in NAFLD
Dr. Moritz Peiseler (La Charité - Germany), discusses new scientific insights into the role of inflammation in NAFLD / NASH. He presents the spectrum of NAFLD and explains how inflammation can drive all the progressive stages of NAFLD. He also reviews hepatocellular carcinoma (HCC) risks and presents several studies and evolving treatments for NASH.
View More ⏩New insights into the role of inflammation in NAFLD
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES